Latest Regulatory Approval News

Amcor plc and Berry Global Group, Inc. have entered into a definitive all-stock merger agreement, positioning the combined entity as a global leader in consumer and healthcare packaging with expected annual synergies of $650 million.

Conrad Asia Energy reports solid progress in Q4 2024 with finalized gas sales agreements and promising LNG studies, despite delayed final investment decisions due to regulatory approvals.

Amcor plc and Berry Global Group have filed their definitive joint proxy statement with the SEC, marking a key milestone in their planned all-stock merger. Shareholder meetings are scheduled for February 25, 2025, as the companies aim to create a global packaging powerhouse.

Matsa Resources has announced a maiden gold reserve of 46,000 ounces at its Devon Pit Gold Mine, supported by a robust pre-feasibility study and all necessary permits, positioning the company for near-term production.

VHM Limited has secured ministerial endorsement for its Goschen Project Environmental Effects Statement, paving the way for a Final Investment Decision and targeted production in 2026. The company also advanced financing and strategic appointments to support its development trajectory.

CD Private Equity Fund II has announced a special unfranked dividend of AUD 0.09 per ordinary unit, payable on February 24, 2025, signaling steady returns for investors.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Tower Limited has appointed CFO Paul Johnston as interim CEO following Blair Turnbull's resignation, with Deputy CFO Angus Shelton stepping in as interim CFO pending regulatory approval.

Australian Rare Earths Limited has secured a $5 million government grant to advance its Koppamurra Rare Earths Project, while initial drilling at its Overland Uranium Project validates promising geological models for uranium deposits.

Neometals Ltd has bolstered its financial position with a A$7.1 million capital raise while progressing key projects including the commissioning of a lithium-ion battery recycling plant in Germany and preparing for maiden gold drilling at Barrambie.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.